Tomosada Yoshikawa
Director/Board Member at KLAB INC.
Tomosada Yoshikawa active positions
| Companies | Position | Start | End |
|---|---|---|---|
| KLAB INC. | Director/Board Member | 2018-03-24 | - |
| Independent Dir/Board Member | 2018-03-24 | - | |
| SUS CO.,LTD. | Director/Board Member | 2018-11-30 | - |
| Corporate Officer/Principal | 2018-09-30 | - | |
| Cross Reality Co., Ltd. | Director/Board Member | 2019-08-31 | - |
Career history of Tomosada Yoshikawa
Former positions of Tomosada Yoshikawa
| Companies | Position | Start | End |
|---|---|---|---|
| TELLA, INC. | Director/Board Member | 2018-02-28 | 2019-03-26 |
| Independent Dir/Board Member | 2018-02-28 | 2019-03-26 | |
| TAIKO PHARMACEUTICAL CO.,LTD. | Chief Administrative Officer | 2009-05-31 | - |
| Director/Board Member | 2007-05-31 | - | |
| Director of Finance/CFO | 2011-01-03 | 2013-05-31 | |
| Investor Relations Contact | 2009-05-31 | - |
Training of Tomosada Yoshikawa
| Babson College | Masters Business Admin |
| Kwansei Gakuin University | Undergraduate Degree |
Statistics
International
| Japan | 7 |
| United States | 2 |
Operational
| Director/Board Member | 5 |
| Independent Dir/Board Member | 2 |
| Chief Administrative Officer | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 3 |
| Technology Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| KLAB INC. | Technology Services |
| SUS CO.,LTD. | Commercial Services |
| TAIKO PHARMACEUTICAL CO.,LTD. | Health Technology |
| Private companies | 2 |
|---|---|
| Cross Reality Co., Ltd. | |
tella, Inc.
 tella, Inc. BiotechnologyHealth Technology tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
- Stock Market
- Insiders
- Tomosada Yoshikawa
- Experience
